Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Source: CNBC Business
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at CNBC Business